Company profile

Trevi Therapeutics, Inc. Insider Trading

TRVI

Every SEC Form 4 insider trading filing for Trevi Therapeutics, Inc. (TRVI) since April 2023 — open-market buys and sells by directors and officers, option exercises, and cluster activity, updated as each filing is reported to the SEC. Why 2023?

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
CIK
0001563880
Filings
73
Insiders
13
Last filing
2026-06-03

Activity summary

No insider transactions in the last 30 days. The most recent was on June 3, 2026, when Meeker David P bought 35,000 shares. 73 filings from 13 insiders are on record below.

Three year balance

Buy and sell value by quarter, Q2 23 to Q2 26. Trevi Therapeutics, Inc. insiders are net sellers across the period shown.

Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q4 25Q1 26Q2 26

Bars below the rule are sales, above are purchases. Largest quarter on the chart is $601K.

90 day insight

Over the last 90 days, Trevi Therapeutics, Inc. insiders bought $0 across 5 transactions with no open-market sales.

  • Most active insider: Meeker David P with 1 transaction totaling $0.

Activity skews bullish — buys outpace sales.

Insider Transactions

Sourced from SEC EDGAR Form 4 filings. Updated hourly.

DateInsiderCompanyTypeSharesPriceValue
Jun 3, 2026Meeker David PTRVI
Award
35,000
Jun 3, 2026Colangelo DominickTRVI
Award
35,000
Jun 3, 2026Heffernan Michael ThomasTRVI
Award
35,000
Jun 3, 2026Mathers Edward TTRVI
Award
35,000
Jun 3, 2026Vanlent AnneTRVI
Award
35,000

45 more transactions hidden

Free account · No credit card required

Building something? Get API access →

Query this yourself

The same rows, over the API.

curl "https://api.form4api.com/v1/transactions?ticker=TRVI" \
  -H "X-Api-Key: $KEY"
Get a key

Top insiders

By total value filed.

Simon FarrellChief Commercial Officer5 filings$227K
Good Jennifer LPresident & CEO2 filings$27K
Sciascia ThomasChief Scientific Officer2 filings$14K
Delfini LisaChief Financial Officer1 filing+$3K
Galletta ChristopherSee Remarks1 filing+$2K

Institutional Ownership

Top 13F-HR holders of Trevi Therapeutics, Inc. as of 2026-06-30

↓ decreasing
Total reported AUM
$488.3M
QoQ change
-69.6%
Reporting period
2026-06-30
#1
BlackRock, Inc.
CIK 0002012383
$95.7M
5.1M shares
#2
BlackRock, Inc.
CIK 0002012383
$74.9M
4.0M shares
#3
State Street Corp
CIK 0000093751
$56.5M
3.0M shares

Data source: quarterly 13F-HR filings — institutional holders report positions within 45 days of quarter end. Joined with insider activity above — see who's loading up institutionally while insiders are trading. Full 13F-HR API →